Professor

MitoRx Therapeutics Strengthens Scientific Advisory Board with Appointment of Four International Experts

Retrieved on: 
Jeudi, mars 7, 2024

OXFORD, United Kingdom, March 07, 2024 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction to arrest the progression of degenerative diseases, announces the appointment of four distinguished international experts to its Scientific Advisory Board (SAB): Caroline Le Guiner PhD, Milos Filipovic PhD, Professor Phil Hansbro PhD, and Professor Annemieke Aartsma-Rus.

Key Points: 
  • OXFORD, United Kingdom, March 07, 2024 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction to arrest the progression of degenerative diseases, announces the appointment of four distinguished international experts to its Scientific Advisory Board (SAB): Caroline Le Guiner PhD, Milos Filipovic PhD, Professor Phil Hansbro PhD, and Professor Annemieke Aartsma-Rus.
  • Dr. Jon Rees, Chief Executive Officer of MitoRx, said, “We are thrilled to welcome Dr.
  • Le Guiner, Dr. Filipovic, Professor Hansbro, and Professor Aartsma-Rus, to our Scientific Advisory Board.
  • She has a visiting professorship at the John Walton Muscular Dystrophy Research Center at the UK’s Newcastle University.

Silk Road Medical Expands TCAR® Portfolio with Launch of Tapered ENROUTE® Transcarotid Stent System

Retrieved on: 
Mardi, mars 5, 2024

This launch expands upon the company’s prior ENROUTE Transcarotid Stent System, offering additional configurations to better tailor the Transcarotid Artery Revascularization (TCAR) procedure to patient anatomy.

Key Points: 
  • This launch expands upon the company’s prior ENROUTE Transcarotid Stent System, offering additional configurations to better tailor the Transcarotid Artery Revascularization (TCAR) procedure to patient anatomy.
  • “New tapered configurations for our ENROUTE Transcarotid Stent System build upon the robust portfolio of Silk Road’s carotid solutions.
  • The ENROUTE Transcarotid Stent System features an optimized cell design balancing lesion coverage and anatomical conformability for long-term plaque stabilization.
  • The stent system was purpose-built for TCAR with a short delivery system for ergonomic and precise stent delivery.

American Urological Association Releases Salvage Therapy for Prostate Cancer Guideline

Retrieved on: 
Jeudi, février 29, 2024

BALTIMORE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO), released the 2024 clinical practice guideline on salvage therapy for prostate cancer.

Key Points: 
  • BALTIMORE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO), released the 2024 clinical practice guideline on salvage therapy for prostate cancer.
  • Understanding the evaluation and appropriate use of salvage therapies for patients with biochemical recurrence is a critical area of prostate cancer care.
  • “Thanks to the incredible expertise of the entire Panel, this guideline helps provide a roadmap that combines the latest advancements with thoughtful recommendations, empowering patients and clinicians alike.”
    This guideline has 30 recommendations and is a useful reference for effective evidence-based care related to salvage therapy for prostate cancer.
  • Salvage therapy for prostate cancer: AUA/ASTRO/SUO guideline part I: introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy.

Simulations Plus and the University of Bath Awarded New FDA Grant

Retrieved on: 
Mardi, mars 5, 2024

“Collaborating with the University of Bath and other partners on this groundbreaking FDA grant is a remarkable opportunity.

Key Points: 
  • “Collaborating with the University of Bath and other partners on this groundbreaking FDA grant is a remarkable opportunity.
  • By doing so, we aim to significantly expedite the regulatory decision-making process, ultimately benefiting patients and the pharmaceutical industry.”
    FDA scientific and program staff will actively collaborate with the University of Bath, Colorado School of Mines, University of Reading, and Simulations Plus.
  • Le Merdy , with assistance from Dr. Jessica Spires and Dr. Jasmina Novakovic at Simulations Plus, will coordinate modeling and simulation activities of the contract.
  • “By combining our expertise with Simulations Plus’ cutting-edge research, we are charting a course towards more efficient drug development and safer healthcare solutions.

Ex-Google DeepMind and Owkin scientists team up to create Bioptimus to build the first universal AI foundation model for biology

Retrieved on: 
Mardi, février 20, 2024

Under the leadership of Professor Jean-Philippe Vert, PhD, Bioptimus unites a world-class team of scientists from Owkin and Google DeepMind alumni to transform ​biology with cutting-edge AI foundation model technologies that capture the various scales of biology.

Key Points: 
  • Under the leadership of Professor Jean-Philippe Vert, PhD, Bioptimus unites a world-class team of scientists from Owkin and Google DeepMind alumni to transform ​biology with cutting-edge AI foundation model technologies that capture the various scales of biology.
  • Top global tech investors Headline, Hummingbird, NJF Capital, Owkin and Top Harvest Capital, as well as notable tech entrepreneur Xavier Niel, have joined the round to create a global leader in AI for biology in France.
  • This holistic understanding of biology across scales will be critical to accelerate biomedical and environmental science.”
    Edward Kliphuis, Partner at Sofinnova Partners, added: “Foundation models in biology are game-changers.
  • Bioptimus stands out by seamlessly blending unparalleled data resources and access, elite talent, and extensive computational power.

Korean Government Delegation and KACES Conclude Successful 3rd UNESCO World Conference on Culture and Art Education

Retrieved on: 
Lundi, février 19, 2024

The Ministry of Culture, Sports and Tourism (MCST, Minister: Yu In-chon) and Korea Arts & Culture Education Service (KACES, President: Park Eun-sil) participated in the 3rd UNESCO World Conference on Culture and Arts Education, held in Abu Dhabi, United Arab Emirates from February 13th to 15th.

Key Points: 
  • The Ministry of Culture, Sports and Tourism (MCST, Minister: Yu In-chon) and Korea Arts & Culture Education Service (KACES, President: Park Eun-sil) participated in the 3rd UNESCO World Conference on Culture and Arts Education, held in Abu Dhabi, United Arab Emirates from February 13th to 15th.
  • View the full release here: https://www.businesswire.com/news/home/20240219103477/en/
    The 3rd UNESCO World Conference on Culture and Arts Education is held in Abu Dhabi, United Arab Emirates (Photo: KOREA ARTS & CULTURE EDUCATION SERVICE)
    Held for the first time since 2010's Seoul event, the 3rd UNESCO World Conference on Culture and Arts Education aimed to reflect evolving social values and adopt the revised Framework for Culture and Arts Education.
  • During the first session, MCST's Culture and Arts Policy Director, Lee Hae-don, gave a presentation titled "A Fair Opportunity for Access to Culture and Arts Education."
  • A MCST official said, “In this conference, which was aimed at discussing the directivity of global culture and arts education, Korea’s leadership in the field of culture and arts education was demonstrated.”
    View source version on businesswire.com: https://www.businesswire.com/news/home/20240219103477/en/

Patient-Reported Outcomes Data from Longest Running Dermatology Study: TARGET-DERM AA Poster Presented at American Academy of Dermatology (AAD) 2024

Retrieved on: 
Vendredi, mars 8, 2024

DURHAM, N.C., March 8, 2024 /PRNewswire/ -- New patient-reported outcomes data presented at AAD 2024 from Target RWE's TARGET-DERM AA registry confirms the high unmet need and significant disease burden in patients with moderate to severe alopecia areata (AA). TARGET-DERM is the largest and most comprehensive longitudinal RWE study observing patients with immune-mediated inflammatory skin conditions in the United States.

Key Points: 
  • Patients with AA have a high unmet medical need due to comorbid conditions and high impact on quality of life.
  • The most common comorbid conditions associated with AA include vitiligo, atopic dermatitis (eczema), Hashimoto's thyroiditis, psoriasis, and systemic lupus erythematosus.
  • TARGET-DERM AA is distinctively positioned to address real-world access to care, disease progression, diagnosis, and treatment in patients with moderate to severe AA.
  • "What's important about our data presented at AAD and TARGET-DERM AA is that we are gaining insights on the impact of the disease.

Alamar Biosciences Announces the Commercial Launch of Ultra-high Sensitivity NULISAseq™ CNS Disease Panel 120 and NULISAqpcr™ pTau-217 Assays

Retrieved on: 
Mardi, mars 5, 2024

FREMONT, Calif., March 5, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, announced today the commercial launch of the NULISAseq CNS Disease Panel 120 for highly multiplexed protein analysis of all the critical pathways implicated in major neurological disorders, and the NULISAqpcr pTau-217 Assay (ALZpath antibody) for focused studies of this important biomarker in dementia research. Both assays benefit from the unparalleled sensitivity of the NULISA™ chemistry and are run on the fully automated ARGO™ HT System that streamlines the time to complete large cohort studies. The launch of these two products represents another important milestone in the company's goal to deliver high-sensitivity protein analysis from biofluids to enable earlier diagnosis of disease and better prediction of therapeutic outcomes. The products are expected to ship in Q2 2024. 

Key Points: 
  • Data demonstrating the superior performance over existing assays highlighted at the Alzheimer's Disease and Parkinson's Disease (AD/PD™ 2024) international conference in Lisbon, Portugal.
  • Both assays benefit from the unparalleled sensitivity of the NULISA™ chemistry and are run on the fully automated ARGO™ HT System that streamlines the time to complete large cohort studies.
  • The Alamar products represent a significant advancement in Alzheimer's Disease research, says Dr. Henrik Zetterberg.
  • This research depends on the availability of biomarkers to detect disease earlier and distinguish between highly related dementia disorders.

Alamar Biosciences Announces the Commercial Launch of Ultra-high Sensitivity NULISAseq™ CNS Disease Panel 120 and NULISAqpcr™ pTau-217 Assays

Retrieved on: 
Mardi, mars 5, 2024

FREMONT, Calif., March 5, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, announced today the commercial launch of the NULISAseq CNS Disease Panel 120 for highly multiplexed protein analysis of all the critical pathways implicated in major neurological disorders, and the NULISAqpcr pTau-217 Assay (ALZpath antibody) for focused studies of this important biomarker in dementia research. Both assays benefit from the unparalleled sensitivity of the NULISA™ chemistry and are run on the fully automated ARGO™ HT System that streamlines the time to complete large cohort studies. The launch of these two products represents another important milestone in the company's goal to deliver high-sensitivity protein analysis from biofluids to enable earlier diagnosis of disease and better prediction of therapeutic outcomes. The products are expected to ship in Q2 2024. 

Key Points: 
  • Data demonstrating the superior performance over existing assays highlighted at the Alzheimer's Disease and Parkinson's Disease (AD/PD™ 2024) international conference in Lisbon, Portugal.
  • Both assays benefit from the unparalleled sensitivity of the NULISA™ chemistry and are run on the fully automated ARGO™ HT System that streamlines the time to complete large cohort studies.
  • We have also partnered with ALZpath, Inc. to bring the performance of their industry standard pTau217 antibody to a new level of sensitivity."
  • This research depends on the availability of biomarkers to detect disease earlier and distinguish between highly related dementia disorders.

Equitable Breakthroughs in Medicine Development Reaches Next Phase Driving Diversity in Clinical Trials in Georgia, South Carolina, Tennessee, and Texas

Retrieved on: 
Mardi, février 27, 2024

NEW HAVEN, Conn., Feb. 26, 2024 /PRNewswire/ -- Equitable Breakthroughs in Medicine Development (EQBMED), led by Yale School of Medicine, Morehouse School of Medicine, the Research Centers in Minority Institutions Coordinating Center (RCMI) at Morehouse School of Medicine, and Vanderbilt University Medical Center, is a partnership bringing clinical trial sites closer to the community to further equity and access for diverse populations. Today, EQBMED announced the selection of the first four Learning Phase sites, moving the needle closer to a scalable and sustainable clinical trial model in historically underserved communities. The partnerships include:

Key Points: 
  • Today, EQBMED announced the selection of the first four Learning Phase sites, moving the needle closer to a scalable and sustainable clinical trial model in historically underserved communities.
  • The program works to increase awareness of clinical trials, address misinformation and historical mistrust, while ensuring the trial is easily accessible.
  • The EQBMED partnership meets sites where they are, building on their strengths and capabilities to become sustainable within the clinical trial ecosystem.
  • "EQBMED is making real progress towards equitable access to clinical trials and enhancing these sites with needed resources."